Street View: Australia's CSL to rely on Behring for revenue growth in near term
** Pharmaceutical co CSL CSL.AX forecast weaker-than-expected annual profit on Tuesday
** CSL shares closed at their lowest level on Tuesday since July 2, falling as much as 5.6%
** CSL's forecast for statutory net profit after tax between $3.2 bln-$3.3 bln on a constant currency basis for FY2025 fell short of Visible Alpha consensus of $3.39 billion
CSL BEHRING A SAVING GRACE
** Brokerages Citi (raises target price to A$345/shr from A$335/shr), Morningstar (maintains fair value estimate of A$310/shr) and Jefferies (reduces price target to A$352/shr from A$355.30/shr) see gross margin for CSL Behring to improve between FY26-FY28
** "We expect Behring gross margin to fully recover to pre-covid levels in FY28" - Citi
** Morningstar and Jefferies expect further cost efficiencies in CSL Behring from rollout of its Rika Plasma Donation System
** Citi and Jefferies see revenue growth from FY25 onwards to mainly be driven by CSL Behring
** However, Citi sees benefits from rollout of Rika Plasma to only reflect from FY26 onwards
Reporting by Shivangi Lahiri in Bengaluru
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
